Skip to main content
Premium Trial:

Request an Annual Quote

FDA OKs Cequent IND for Oral RNAi Drug

Premium

Cequent Pharmaceuticals announced this week that its new drug application for an oral RNAi-based treatment for advanced familial adenomatous polyposis has been approved by the US Food and Drug Administration.

FAP is an inherited, colorectal cancer syndrome characterized by the growth of colorectal polyps. Though the polyps are initially benign, they become malignant in nearly all cases in the absence of colectomy, according to the company.

The drug, dubbed CEQ508, is designed to inhibit the oncogene beta-catenin, which is expected to prevent new polyp formation and possibly slow the progression to malignancy of existing ones.

The company said it is now working with the clinical center where a proposed phase I trial of the drug is to be run, the Fred Hutchinson Cancer Research Center in Seattle, to obtain the necessary institutional approvals. The study is slated to begin in early 2010.

Cequent first filed the IND in November (see RNAi News, 11/19/2009).

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.